Processing

Please wait...

Settings

Settings

Goto Application

1. EP0832223 - C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY AND METHODS FOR PREPARATION

Office European Patent Office
Application Number 96918669
Application Date 04.06.1996
Publication Number 0832223
Publication Date 01.04.1998
Publication Kind A1
IPC
A61K 38/17
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
C12N 15/12
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
12Genes encoding animal proteins
C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
CPC
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/472
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
4701not used
472Complement proteins, e.g. anaphylatoxin, C3a, C5a
C07K 2319/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2319Fusion polypeptide
Applicants CIBA GEIGY AG
Inventors VAN OOSTRUM JAN
VAN HEEKE GINO
SCHMITZ ALBERT
Designated States
Priority Data 9602422 04.06.1996 EP
46264895 05.06.1995 US
08463224 05.06.1995 US
08463377 05.06.1995 US
Title
(DE) ANTAGONISTEN VON C 5A-REZEPTOREN OHNE AGONISTISCHE WIRKUNG UND VERFAHREN ZU DEREN HERSTELLUNG
(EN) C5a RECEPTOR ANTAGONISTS HAVING SUBSTANTIALLY NO AGONIST ACTIVITY AND METHODS FOR PREPARATION
(FR) ANTAGONISTES DES RECEPTEURS DE C5a NE PRESENTANT SENSIBLEMENT AUCUNE ACTIVITE AGONISTE ET LEURS PROCEDES DE PREPARATION
Abstract
(EN)
Disclosed are polypeptide analogues or derivatives of human C5a which are C5a receptor antagonists that exhibit substantially no analphylatoxin or agonist activity, and derivatives of the analogues, and dimeric forms of the analogues or derivatives. DNA molecules encoding the polypeptides and methods of making the analogues are also provided. Pharmaceutical formulations containing a C5a analogue or derivative, are used therapeutically in the treatment of C5a-mediated diseases and inflammatory conditions in mammals, and prophylactically to prevent or reduce inflammation caused by an event which causes inflammation or aggravates an existing inflammatory condition, respectively. Further disclosed are antibodies specific to the C5a analogues, derivatives thereof, and dimers of the analogues and derivatives which exhibit substantially no cross-reactivity with human C5a. The antibodies are used to detect or quantify circulating C5a analogue or derivative, as well as to modify, e.g., neutralize, the activity of the C5a receptor antagonist $i(in vivo).

(FR)
Analogues polypeptidiques ou dérivés de C5a humaine, antagonistes des récepteurs de C5a ne présentant sensiblement aucune activité d'anaphylatoxine ou d'agoniste, et dérivés de ces analogues, ainsi que les formes dimères des analogues ou des dérivés. L'invention concerne également des molécules d'ADN codant les polypeptides et des procédés de production des analogues. Des formulations pharmaceutiques contenant un analogue ou un dérivé de C5a sont employées en thérapeutique dans le traitement des maladies à médiation par C5a et des états inflammatoires chez des mammifères, et en prophylaxie pour prévenir ou réduire les inflammations provoquées par un événement causant une inflammation ou aggravant un état inflammatoire préexistant, respectivement. Sont également décrits des anticorps spécifiques aux analogues de C5a, à leurs dérivés, et aux dimères des analogues et dérivés ne présentant sensiblement aucune réactivité croisée avec la C5a humaine. Les anticorps sont utilisés pour détecter ou quantifier la circulation d'analogue ou de dérivé de C5a, ainsi que pour modifier, par exemple neutraliser, l'activité de l'antagoniste du récepteur de C5a $i(in vivo).